A Danish population-based cohort study of newly diagnosed asthmatic children's care pathway – adherence to guidelines by Moth, Grete et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
A Danish population-based cohort study of newly diagnosed 
asthmatic children's care pathway – adherence to guidelines
Grete Moth*1,2, Peter O Schiotz1 and Peter Vedsted2
Address: 1Danish Paediatric Asthma Centre, Aarhus University Hospital, Skejby, Denmark and 2The Research Unit for General Practice, University 
of Aarhus, Denmark
Email: Grete Moth* - grete.moth@alm.au.dk; Peter O Schiotz - poa@sks.aaa.dk; Peter Vedsted - p.vedsted@alm.au.dk
* Corresponding author    
Abstract
Background:  Asthma is the most common chronic disease in childhood. Large variations exist
concerning the number of children being treated by general practitioners and by specialists. Consequently,
health related costs due to this disease vary as care by specialists is more expensive compared with care
by general practitioners. Little is known of the consequences of these variations concerning the quality of
care. The aim of the study was to analyse associations between care providers and adherence to guidelines
concerning frequency of contacts with the health service due to asthma.
Methods: A cohort study was performed of 36,940 incident asthmatic children's (aged 6–14) contacts
with the health service using the unique personal registration number to link data from five national
registries. The prevalence ratios were calculated for associations between provider (general practitioner,
primary care specialist, hospital specialist or both GP and specialist) and adherence with guidelines
concerning three indicators of quality of care pathway: 1) diagnostic examination of lung function at start
of medical treatment 2) follow-up the first six months and 3) follow-up the next six months. The
associations were adjusted for sex, age, socioeconomic status, county, and severity of disease.
Results: Most children (70.3%) had only been seen by their GP. About 80% of the children were treated
with inhaled steroids, 70% were treated with inhaled steroids as well as inhaled beta2agonists and 13%
were treated with inhaled beta2agonists only. A total of 12,650 children (34.2%) had no registered asthma-
related contacts with the health service except when redeeming prescriptions. Care was in accordance
with guidelines in all three indicators of quality in 7% of the cases (GPs only: 3%, primary care specialists
only: 16%, hospital specialists: 28%, and both GP and specialists: 13%). Primary care specialists had a 5.01,
hospital specialists a 8.81 and both GP and specialists a 4.32 times higher propensity to provide a clinical
pathway according to guidelines compared to GPs alone.
Conclusion: The majority of the children were seen in general practice. Hospital specialists provided care
in accordance with guidelines nine times more often compared with GPs, but still only one quarter of these
children had pathways in accordance with guidelines. It is relevant to study further if these lacks of
adherence to guidelines have implications for the asthmatic children or if guidelines are too demanding
concerning frequency of follow-up or if asthmatic children should be stratified to different care pathways.
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Background
Asthma is the most common chronic disease in childhood
and the associated public health expenditure is high [1-5].
Ideally, care for asthmatic children is carried out accord-
ing to international and national guidelines, as care com-
plying with guidelines is related to improved patient
outcome [6,7]. According to guidelines care of children
with mild asthma can be managed by general practition-
ers (GPs) [8-10]. This is in line with the explicit intention
of the overall health plans of the Danish counties that
health care is to be organized with mild cases managed by
GPs and more severe or problematic cases are referred to
specialists. This is to ensure the most efficient use of the
available health resources. In practice, paediatric asthma
care is managed within a framework defined by traditions,
guidelines, and available resources depending on political
and administrative decisions in the counties concerning
organization of health care and the division of care
between general practice, specialists in primary health
care, and hospitals.
However, despite intentions to organize care in the most
efficient way, there are considerable differences concern-
ing the number of asthmatic children being treated by GPs
and by specialists internationally [11,12] as well as in
Denmark. This is shown in previous studies by our group
[13,14]. These variations indicate systematic differences in
the organization of health care for asthmatic children.
This is interesting in the perspectives of health services
research and quality of care. Therefore, it is relevant to
study these differences in care pathways of asthmatic chil-
dren in order to measure the impact of care providers on
quality of care.
In Denmark it is possible to study care pathways in a
nationwide scale due to existence of national registries
and the unique personal registration number (PRN),
assigned to all citizens [15]. The PRN permits data from
the national registries containing data on all Danish citi-
zens at an individual level to be linked [16-18].
Aim
The aim of this study was to map out incident asthmatic
children's care pathways six months prior to and the first
year following start of medical treatment to measure asso-
ciations between 1) characteristics of the children and
their care pathways and 2) type of care provider and
adherence to guidelines.
Methods
A historical population-based cohort study was con-
ducted of asthmatic children's care pathways for 18
months using registry data linked from five national regis-
tries.
Study population
Children born between 1988 and 1996 using anti-asth-
matic medication in the period from 1996 throughout
2004 formed a cohort of 6–14-year-old asthmatic chil-
dren. We used a validated method based on redeemed
prescriptions described elsewhere [19] to include asth-
matic children. A short presentation of the method is
given in Appendix 1. Focusing on incident asthmatic chil-
dren we restricted inclusion to children that redeemed
anti-asthmatic medication for the first time between 1999
and 2004 or after a medication free period of at least two
years. Children that moved between counties during the
observation period were excluded.
Study period
The asthmatic children were followed from six months
before until 12 months after starting their anti-asthmatic
treatment in the period from 1999 throughout 2004.
Description and categorization of data
Data on anti-asthmatic medication were identified by the
ATC codes described in Appendix 2 and were obtained
from the Register of Medicinal Product Statistics [17].
Data obtained included: the PRN number, ATC code,
number of packages, and date of dispensing. Use of pack-
ages was summed up for each month for the following
five types of medication: inhaled steroid, inhaled short-
acting beta2agonist, inhaled long-acting beta2agonist,
fixed combinations of inhaled steroid and long-acting
beta2agonist, and leukotrien receptor antagonist. Severity
of disease categories were based on number of packages in
the study period: mild: 1–4, moderate: 5–8, and severe: >
8.
Data from the National Danish Patient Registry [16] on
visits to outpatient clinics and hospital admissions due to
one of the asthma diagnoses shown in Appendix 3 were
summed up for each month.
In Denmark every child is registered with a GP and this GP
is gatekeeper to the rest of the health care system. Contacts
with GPs and primary care specialists were also summed
up for each month. As these are not registered with a diag-
nosis in the National Health Insurance Service Registry
[18] but by the performed examination, we decided to
include contacts that were registered by a peakflow test, a
spirometry, or a reversibility test as a proxy for a visit due
to asthma.
For each child the visits to GPs and specialists in primary
care and the contacts to hospitals were used to define the
provider that had managed the care of the child during the
whole 18 months study period (six months prior to and
12 months after medication start). The study populationBMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
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was divided into four groups depending on provider of
asthma care during the whole study period:
1) Contacts only with GP.
2) Contacts only with specialist in the primary health care
sector.
3) Contacts only with specialist at out-patient clinic/hos-
pital.
4) Contacts with GP as well as specialists.
Thus, if a child had a contact to the GP at start of medica-
tion and no further contacts the GP was defined as the
care provider for the whole period. If medication was ini-
tiated by a specialist and the child had performed a lung
function test at the GPs at some time during the observa-
tion period the child was placed in provider group 4.
Data on parent's marital status (single or cohabiting/mar-
ried), education level, and annual income were acquired
for the year of inclusion from Statistics Denmark [20]. In
case of divorce the child was presumed to live with the
mother, as is the case for more than 90% of children of
divorced parents in Denmark [21]. Data on education of
the parents were categorized into three groups: short: pri-
mary and high school (< 14 years), intermediate: short or
intermediate higher education (14–18 years), and long:
higher education (> 18 years). Likewise, data on income
were categorized in four groups 1: < 150,000 (approxi-
mately equivalent to unemployment benefit (20,000
Euro)). 2: 150,000–250,000. 3: 250,000–350,000. 4: >
350,000 (DKK) (1 Euro = 7.5 DKK).
Guidelines
Recommendations concerning asthmatic children's care
pathway were extracted from the GINA-guidelines and the
British and Canadian national guidelines for paediatric
asthma [8-10]. We focused on:
1) Diagnostic examination of lung function during the 6-
month period before or at start of medical treatment.
2) Follow-up at least once during the first six months fol-
lowing start of medical treatment.
3) Follow-up at least once during the next six months.
An overall indicator of quality of care was applied based
on whether all the indicators 1–3 were achieved.
Analysis
Associations between characteristics of the children (gen-
der, age, socioeconomic factors, and disease severity) and
adherence to guidelines were calculated by use of a gener-
alized linear model (GLM). Further, we calculated the
association between care provider and the adherence to
guidelines adjusted for the children's gender, age, county,
socioeconomic status, and severity of disease. Associa-
tions were calculated as the prevalence difference (PD)
and the prevalence ratio (PR) between care providers. The
PR is the ratio between the prevalences where the odds
ratio is the ratio between odds. We preferred the PR to the
odds ratio because the prevalences were high (> 20%) and
the odds ratios therefore would tend to overestimate the
PR [22]. Analyses were performed by use of STATA 9.
Ethics
All data were stored at Statistics Denmark. We obtained
access to an encrypted version of the data after approval
by The Danish Data Protection Agency, the Danish
National Board of Health, and Statistics Denmark (Project
no. 702063).
Results
During the period 1999–2004 anti-asthmatic drugs were
dispensed to 46,043 6–14 year-old asthmatic children. Of
these, 37,283 (81.0%) were incident asthmatics. Due to
change of address between counties 343 children were
excluded leaving 36,940 children for analyses.
Characteristics of the children in the cohort are presented
in Table 1. Most of the children (70.3%) had only been
treated by their GP including 12,650 children (34.2%)
who had no registered asthma related contacts with the
health service except for prescriptions for anti-asthmatic
medication. About 80% were treated with inhaled ster-
oids and 70% had been prescribed inhaled beta2agonists
as well. Approx. 13% were treated with inhaled
beta2agonists only. Half of the children were categorised
as mild cases of asthma and 36% and 15% as moderate
and severe asthma, respectively.
In Table 2, 3, 4 the association between child characteris-
tics of the children and adherence to guideline is shown.
The more severe the asthma was, the more often the lung
function test was done. Children aged 9–11 and 12–14
years had a higher propensity to receive a lung function
test in the diagnostic period and during the first six
months of follow up compared with 6–8 year-old chil-
dren. Concerning socioeconomic factors children from
low income families had a small but statistically signifi-
cantly lower propensity of receiving a diagnostic lung
function test and follow-up during the first six months.
Children from two-parent families were more often mon-
itored with follow-up visits compared with single-parent
children.BMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
Page 4 of 9
(page number not for citation purposes)
Table 5 shows the association between quality and pro-
vider of care with GPs as the reference group. The preva-
lence of overall quality of care was in accordance with
guidelines for 3%, 16%, 28%, and 13% of the children
cared for by GPs only, by primary care specialist only, by
specialists at hospitals only or by both GPs and specialists,
respectively. The PR of managing a care pathway accord-
ing to guidelines by primary care specialists compared to
GPs was 5.01 and by hospital specialists compared to GPs
PR was 8.81 and by both specialists and GP PR was 4.32.
When excluding the 12,650 children without lung-spe-
cific contacts with the health service in order to compare
GPs that actually performed examinations and monitored
the children with specialist care, the associations for hav-
ing a care pathway according to guidelines were reduced
to 2.62 (2.62–3.04) for primary care specialists, and to
Table 1: Characteristics of children in the cohort (n = 36,940)
No. of children (%)
Demographic Gender Boys 22,480 (60.9)
Girls 14,460 (39.1)
Age at inclusion (mean: 9.2 years) 6–8 years 18,025 (48.8)
9–11 years 14,174 (38.4)
12–13 years 4,741 (12.8)
Socioeconomic status Family characteristic in the year of 
inclusion
Two-parent family 30,120 (81.6)
Single-parent family 6,662 (18.0)
No information 158 (0.4)
Parent's education level 1. Primary and high school 21,998 (59.6)
2. Short or intermediate higher 
education
10,194 (27.6)
3. Long higher education 4,590 (12.4)
No information 158 (0.4)
One parent's income in the year of 
inclusion (DKK)
1. < 150,000 5,659 (15.3)
2. 150,000–250,000 13,733 (37.2)
3. 250,000–350,000 12,000 (32,5)
4. > 350,000 5,389 (14.7)
No information 159 (0.3)
Geograhpy Distribution of children in the 
counties
Mean (min – max) 2,639 (196 – 6,675)
Overall share of asthmatic children 
(min-max)
4.1% (3.8 – 7.4)
GPs or specialists as healthcare 
providers in the study period
Contact only with GPs with examination of lung function 13,316 (36.1)
Contact only with GPs without examination of lung function 12,650 (34.2)
Contact only with primary care specialists 1,286 (3.5)
Contact only with specialists at outpatient clinics 2,594 (7.0)
Contact with both GPs and specialists 7,094 (19.2)
Medical treatment in 12 months Inhaled steroids 29,912 (81.0)
Inhaled short-acting beta2 agonists 29,741 (80.5)
Long-acting beta2 agonists 5,225 (14.2)
Inhaled steroids and long-acting beta2 agonists in a fixed combination 2,781 (7.5)
Leukotrien receptor antagonists 1,437 (3.9)
Inhaled steroids only 3,547 (9.6)
Inhaled beta2 agonists only 4,857 (13.2)
Inhaled steroids and beta2 agonists (incl. fixed combinations of steroid and 
long-acting beta2agonists)
25,755 (69.7)
Severity of disease No. of packages of anti-asthmatic drugs:
Mild: ≤ 4 18,046 (48.8)
Moderate: 5–8 13,290 (36.0)
Severe: > 8 5,604 (15.2)BMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
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4.59 (4.16–5.06) for hospital specialists compared with
GPs, and for both specialists and GP compared with GPs
only PR was 2.26 (2.05–2.48). Accordance with guide-
lines on all three indicators of care pathway was the case
for 9.2% of the children.
Table 2: Association between characteristics of children and quality of care measured by lung function tests at start of medical 
treatment (n = 36,781)
Examination of lung function at start of medical treatment
P (No.) PD (95% CI) PR (95% CI) Adj. PR (95% CI) P-values
Gender Girl 0.42 (6,107) ref 1 1
Boy 0.43 (9,656) 0.01 (-0.03–0.02) 1.02 (0.99–1.04) 1.02 (0.99–1.04) 0.170
Age 6–8 0.39 (7,104) ref 1 1
9–11 0.45 (6,369) 0.06 (0.04–0.07) 1.14 (1.11–1.17) 1.15 (1.12–1.18) < 0.001
12–14 0.48 (2,290) 0.09 (0.07–0.11) 1.23 (1.18–1.27) 1.26 (1.22–1.3) < 0.001
SES Single 0.42 (2,797) ref 1
Cohabiting 0.43 (12,914) 0.01 (-0.0–0.02) 1.02 (0.99–1.05) 1.00 (0.96–1.03) 0.748
Education 1 0.43 (9,347) ref 1 1
2 0.43 (4,425) 0.01 (0.0–0.02) 1.02 (0.99–1.05) 1.00 (0.97–1.03) 0.923
3 0.42 (1,939) 0.0 (-0.02–0.01) 0.99 (0.96–1.03) 1.0 (0.97–1.03) 0.838
Income 1 0.41 (2,297) ref 1
2 0.43 (5,840) 0.02 (0.0–0.04) 1.05 (1.01–1.09) 1.04 (1.0–1.08) 0.050
3 0.44 (5,268) 0.03 (0.02–0.05) 1.08 (1.04–1.12) 1.07 (1.03–1.12) < 0.001
4 0.43 (2,306) 0.02 (0.0–0.04) 1.05 (1.01–1.10) 1.05 (1.01–1.1) 0.029
Severity of disease Mild 0.40 (7,162) ref 1 1
Moderate 0.45 (5,927) 0.05 (0.04–0.06) 1.12 (1.1–1.15) 1.13 (1.1–1.16) < 0.001
Severe 0.48 (2,674) 0.08 (0.07–0.1) 1.20 (1.16–1.24) 1.22 (1.18–1.26) < 0.001
Table 3: Association between characteristics of children and quality of care measured by lung function tests during follow-up in the 
first six months after start of medication (n = 36,781)
Follow up 1–6 months after start of medical treatment
P (No.) PD (95% CI) PR (95% CI) Adj. PR (95% CI) P-values
Gender Girl 0.42 (6,008) ref 1 1
Boy 0.41 (9,298) 0.00 (-0.01–0,01) 1.00 (0.97–1.02) 0.99 (0.97–1.01) 0.353
Age 6–8 0.39 (6,994) ref 1 1
9–11 0.44 (6,170) 0.05 (0.04–0.06) 1.12 (1.09–1.15) 1.14 (1.11–1.17) < 0.001
12–14 0.45 (2,142) 0.06 (0.05–0.08) 1.17 (1.12–1.21) 1.23 (1.19–1.27) < 0.001
SES Single 0.40 (2,655) ref 1 1
Cohabiting 0.42 (12,612) 0.02 (0.01–0.03) 1.05 (1.02–1.09) 1.03 (0.99–1.06) 0.004
Education 1 0.42 (9,130) ref 1 1
2 0.42 (4,271) 0.00 (-0.01–0.02) 1.01 (0.98–1.04) 0.98 (0.95–1.01) 0.148
3 0.41 (1,866) 0.0 (-0.02–0.01) 0.98 (0.94–1.02) 0.97 (0.93–1.01) 0.114
Income 1 0.39 (2,202) ref 1 1
2 0.41 (5,686) 0.03 (0.01–0.04) 1.06 (1.02–1.11) 1.05 (1.01–1.09) 0.019
3 0.43 (5,126) 0.04 (0.02–0.05) 1.10 (1.06–1.14) 1.08 (1.04–1.12) < 0.001
4 0.42 (2,252) 0.03 (0.01–0.05) 1.07 (1.03–1.12) 1.07 (1.02–1.12) 0.008
Severity of disease Mild 0.35 (6,223) ref 1 1
Moderate 0.47 (6,208) 0.12 (0.11–0.13) 1.36 (1.32–1.39) 1.37 (1.33–1.4) < 0.001
Severe 0.51 (2,875) 0.17 (0.15–0.18) 1.49 (1.44–1.53) 1.51 (1.46–1.56) < 0.001BMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
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Discussion
Main findings
Evaluated on the basis of three quality indicators concern-
ing care pathway 3% of the asthmatic children had been
followed according to guidelines by GPs compared with
16% and 28% of children followed by primary care spe-
cialists and hospital specialists, respectively. Therefore,
care by primary care specialists, by hospital specialists and
by GPs and specialists in combination was 5.01, 8.81, and
4.32 times more associated with care in accordance with
guidelines compared with care by GPs only. Older chil-
dren received more diagnostic lung function tests and ini-
tial follow up than younger children. Diagnostic lung
function tests and initial follow up according to guide-
lines was more often the case for older children and for
children from families with a higher income. Children
from two-parent families were more often monitored
with follow-up visits compared with single-parent chil-
dren. Children with moderate or severe asthma were more
likely to have a care pathway in accordance with guide-
lines than children with mild asthma.
Strengths, limits, and bias
The method to identify the population of asthmatic chil-
dren (Appendix 1) has been shown to have a sensitivity of
64% which might introduce selection bias in direction of
including those with most severe asthma. However, with
a specificity of 92% [19] the excluded children can be
assumed to have mild or no asthma at all. Thus, including
these children may have implied more serious selection
bias and problems with generalisability.
Data on paediatric asthma diagnoses in the Danish
National Patient Registry have been examined recently
and found valid [23]. Data on contacts with GPs and spe-
cialists are based on an electronic registration of remuner-
ated services carefully registered by the provider. Data on
use of medication are based on the automatically gener-
ated list from all pharmacies of dispensed medicine to
patients. The aggregated monthly health service use
ensured a reasonable measure to report without losing too
much information.
According to the guidelines the diagnosis of asthma is pri-
marily based on the medical history but lung function
tests are recommended to confirm the diagnosis and to
monitor in the course of asthma. In the study we primarily
wanted to map out the asthma related care pathways of
the children using registry data and this was simple for the
contacts to hospitals as these were registered by a diagno-
sis. However, lack of diagnoses linked to children's visits
in the primary health care sector forced us to use data on
examinations of lung function only
This means that we have missed follow-ups that were car-
ried out without examinations of lung function. Conse-
quently, we have underestimated the number of visits to
GPs. It can be discussed whether a lung function test is
needed to diagnose and monitor asthma, or if a thorough-
medical history might be as fruitful. However, as approx-
imately 90 % of Danish GPs have spirometry equipment
and peakflow meters are available free to some GPs and at
a low cost to others it is likely that a knowledgeable doctor
would want an objective measure of a lung function.
Thus, although we might have missed some follow-up vis-
its we believe that lung function measurements are a suit-
able proxy for an asthma follow-up in compliance with
the guidelines.
Our result that older children receive more tests of lung
function than the 6–8-year-olds may be explained by the
doctors not expecting the young children to be able to
manage the technique. However, as peakflow test and
spirometry is recommended from the age of 5–6 accord-
ing to guidelines, the indicator was applied for this age-
group as well.
We did not use Defined Daily Dose (DDD) to measure
medication use as DDDs is the documented standard dose
for adults. Furthermore, summing up DDDs would be
meaningless, as the five categories of anti-asthmatic med-
ication in the present study are made up by different types
of medicine with different DDDs. Instead, we calculated
the sum of packages to estimate severity of asthma.
Clearly, the three indicators do not represent a proper
standard in cases of severe and persistent asthma. These
cases are often referred to specialist care and by definition
monitored more closely. This implies a problem of case
mix in the present study, as GPs have a larger share of
uncomplicated cases and thereby more easily risk exceed-
ing six months between checks. Clinical data were not
available to adjust for case mix due to severity of disease
which even in clinical studies is complicated [24,25].
However, we used the number of packages of anti-asth-
matic medication dispensed to the children as a proxy of
severity of asthma in order to adjust for it. The chosen var-
iable of severity is obviously dependent upon the chil-
dren's adherence to the treatment and may as such to
some degree be an expression of this. In case of this a child
reimbursing too few drugs will be misclassified. However,
a child not adhering to the treatment of inhaled steroid,
which may often be the case, can be expected to need
more drug of the reliever type and hence it will be classi-
fied as a more severe case anyway. The categories of sever-
ity showed good consistency with the clinical pathways
found indicating that they to some degree serve the pur-
pose. Such misclassification would tend to diminish the
association towards no associationBMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
Page 7 of 9
(page number not for citation purposes)
Though the diagnosis of asthma is primarily based on the
medical history and the effect of lung function tests can be
discussed these objective measures provide complemen-
tary information valuable in diagnosing and monitoring
different aspects of asthma control according to the guide-
lines. As the aim of the study was to relate the care path-
ways of the children to the guidelines these
recommendations of lung function tests were included.
It is worth noticing that concerning frequency of visits the
guidelines state that the condition and treatment of asth-
matic children are to be reviewed every six months as a
minimum. Due to lack of research studies into this area
this recommendation is not based on evidence but is pre-
sumably an expression of the general consensus on this
subject derived from clinical experiences. However,
despite the lack of evidence not mentioning the impor-
tance of follow-up would be a mistake considering the
chronic and fluctuating nature of the disease. Schatz et al.
in their study of frequency of follow-up visits concluded
that adults with moderate persistent asthma did not need
follow-up visits more often than every six months [26]
Unlike this the present study can be expected to include
also the mild persistent asthma cases due to the identifica-
tion method [19]. Consequently, it may be a matter of dis-
cussion if lack of accordance with guidelines concerning
the mild cases implies poor quality. In this respect it is
worth considering that guidelines are developed by spe-
cialists with thorough knowledge of and experience with
asthma in the most severe cases. In this study, although
the very mild cases were excluded beforehand, specialists
had been in contact with only 30% of the children. Con-
sequently, the asthmatic children consulting specialists is
a small and selected group with more severe asthma. So,
the question is if guidelines on frequency of follow-up are
relevant for all asthmatic children. It is especially worth
considering if the required frequency of follow-up is rea-
sonable or if asthmatics with mild intermittent and mild
persistent asthma can manage with less frequent visits.
Therefore, it may be more cost-effective to stratify children
with asthma to different pathways according to their
needs.
Conclusion
In this study, adherence to guidelines concerning diagno-
sis and frequency of follow-up for Danish asthmatic
schoolchildren were achieved in 7% of the cases. Care by
hospital specialists alone was nine times more in accord-
ance with guidelines compared with care by GPs. How-
ever, even in the hands of hospital specialists, all three
guideline standards for care were met in only one fourth
of the cases. The results of this study have lead to another
study from our group on whether lack of correspondence
with guidelines concerning care pathways as defined in
this study implies an actual risk for the asthmatic children
of being admitted to hospital due to asthma.
Table 4: Association between characteristics of children and quality of care measured by lung function tests during follow-up in the 
months 7–12 after start of medication (n = 36,781)
Follow up 7–12 months after start of medical treatment
P (No.) PD (95% CI) PR (95% CI) Adj. PR (95% CI) P-values
Gender Girl 0.23 (3,317) ref 1 1
Boys 0.25 (5,599) 0.02 (-0.0–0.03) 1.09 (1.05–1.13) 1.05 (1.01–1.09) 0.008
Age 6–8 0.24 (4,380) ref 1 1
9–11 0.25 (3,520) 0.01 (0.0–0.05) 1.02 (0.98–1.06) 1.07 (1.03–1.11) 0.001
12–14 0.21 (1,016) -0.03 (-0.04- -0.02) 0.88 (0.83–0.94) 1.01 (0.95–1.07) 0.767
SES Single 0.23 (1,515) ref 1 1
Cohabiting 0.25 (7,389) 0.02 (0.01–0.03) 1.08 (1.03–1.13) 1.06 (1.01–1.11) 0.020
Education 1 0.24 (5,213) ref 1 1
2 0.25 (2,542) 0.01 (0.0–0.02) 1.05 (1.01–1.1) 1.01 (0.97–1.06) 0.627
3 0.25 (1,149) 0.01 (0.0–0.03) 1.06 (1.0–1.12) 1.05 (0.99–1.11) 0.102
Income 1 0.24 (1,378) ref 1 1
2 0.24 (3,319) 0.00 (-0.02–0.01) 0.99 (0.94–1.05) 0.97 (0.91–1.02) 0.189
3 0.25 (2,942) 0.00 (-0.01–0.02) 1.01 (0.95–1.06) 0.97 (0.92–1.03) 0.288
4 0.24 (1,265) -0.01 (-0.03–0.01) 0.96 (0.90–1.03) 0.92 (0.86–0.99) 0.018
Severity of disease Mild 0.14 (2,577) ref 1 1
Moderate 0.31 (4,090) 0.17 (0.16–0.17) 2.16 (2.06–2.25) 2.15 (2.06–2.24) < 0.001
Severe 0.40 (2,249) 0.26 (0.25–0.27) 2.81 (2.68–2.95) 2.79 (2.66–2.93) < 0.001BMC Health Services Research 2008, 8:130 http://www.biomedcentral.com/1472-6963/8/130
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Appendix 1
Description of the method to identify a population of 
asthmatic children
A register-based study of 125,907 6–14 year-old Danish
children identified 9,695 children who had redeemed at
least one anti-asthmatic drug prescription in 2002. The
asthma diagnosis in these children was validated by dis-
charge information from the Danish National Patient
Registry and by general practitioners based on a question-
naire in which they were asked whether the children in
question listed with their practice according to his/her
medical knowledge had the diagnosis of asthma. Models
based on combinations of different types of drugs were
tested to find the best model including as many children
with a validated diagnosis as possible and excluding as
many false positives as possible. Different time windows
were tested both concerning detecting the children and
concerning observation period of redeeming prescrip-
tions.
The highest specificity of 0.86 (CI: 0.84–0.87) together
with a sensitivity of 0.63 (CI: 0.62–0.65) was seen in the
Table 5: Association between quality of care (adherence to guidelines measured by three single indicators and overall) and provider of 
care (n = 36,781)
Indicators of quality of treatment
Examination of lung 
function prior to or 
at start of med. 
treatment
Follow-up 1–6 
months after start 
of med. treatment
Follow-up 7–12 
months after start 
of med. treatment
Overall quality of 
care (all three 
indicators)
GPs (Ref) n = 25,843 P (No.) 0.34 (8,926) 0.30 (7,693) 0.11 (2,786) 0.03 (692)
Primary care 
specialists n = 1,282
P (No.) 1.00 (1,286) 0.52 (666) 0.32 (406) 0.16 (201)
PD (95% CI) 0.66 (0.65–0.66) 0.22 (0.19–0.25) 0.21 (0.18–0.23) 0.13 (0.11–0.15)
PR (95% CI) 2.91 (2.86–2.96) 1.75 (1.65–1.85) 2.94 (2.70–3.21) 5.87 (5.07–6.79)
Adj PR (95% CI) 2.88° (2.82–2.93) 1.68 (1.59–1.78) 2.59 (2.38–2.83) 5.01 (4.32–5.80)
P-values < 0.001 < 0.001 < 0.001 < 0.001
Specialists at 
hospital n = 2,580
P (No.) 1.00 (2.594) 0.57 (1,488) 0.54 (1,406) 0.28 (716)
PD (95% CI) 0.66 (0.65–0.66) 0.28 (0.26–0.30) 0.44 (0.42–0.45) 0.25 (0.23–0.27)
PR (95% CI) 2.92 (2.86–2.96) 1.94 (1.86–2.01) 5.05 (4.81–5.31) 10.4 (9.41–11.4)
Adj PR (95% CI) 2.98 (2.93–3.04) 1.91 (1.84–1.99) 4.48 (4.26–4.72) 8.81 (7.98–9.73)
P-values < 0.001 < 0.001 < 0.001 < 0.001
GPs and specialists 
n = 7,070
P (No.) 0.42 (2,957) 0.77 (5,459) 0.61 (4,318) 0.13 (949)
PD (95% CI) 0.08 (0.06–0.09) 0.47 (0.46–0.49) 0.50 (0.49–0.51) 0.11 (0.10–0.12)
PR (95% CI) 1.21 (1.17–1.25) 2.60 (2.54–2.66) 5.67 (5.45–5.90) 5.02 (4.57–5.52)
Adj PR (95% CI) 1.22 (1.18–1.26) 2.52 (2.46–2.58) 5.04 (4.84–5.26) 4.32 (3.92–4.76)
P-values < 0.001 < 0.001 < 0.001 < 0.001
° Poisson regression
Adjusted for age, gender, socioeconomic status, county, and severity of disease
P: Prevalence, PD: Prevalence difference, PR: Prevalence ratioPublish with BioMed Central    and   every 
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model that included children that during a 12-month
period had redeemed a prescription of any anti-asthmatic
drug except beta2-agonist as liquid and except inhaled
beta2 agonist or inhaled steroid only once. The positive
predictive value of the method was 0.92, meaning that
92% of the children identified by this method actually
had the diagnosis. Adding six months observation time
did not improve the specificity significantly (0.87 (CI:
0.85–0.88)) but resulted in a statistically significantly
lower sensitivity (0.59 (CI: 0.58–0.60)) [19].
Appendix 2
Asthma diagnoses (ICD10) of data from The National 
Patient Registry [27]
Asthma: J45. Predominantly allergic asthma: J45.0. Non-
allergic asthma: J45.1. Mixed asthma: J45.8. Asthma,
unspecified: J45.9. Status asthmaticus: J46.9
Appendix 3
Anti-asthmatic drugs listed by ATC-codes for data on use 
of medication [28]
Inhaled steroid: R03BA01, R03BA02 and R03BA05.
Inhaled shortacting beta2 agonists: R03AC02, R03AC03
and R03AC04. Longacting beta2 agonists: R03AC13 and
R03AC12. Inhaled steroid and longacting beta2 agonists
in a fixed combination: R03AK06 and R03AK07. Leukotr-
ien receptor antagonists: R03DC03
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